Long-term results of dose density therapy in patients with aggressive lymphoma

Annals of Hematology

Volumn 84, Issue 4, 2005, Pages 217-222

  Fridrik, Michael A ^a   Hausmaninger, Hubert ^b   Linkesch, Werner ^c   Greil, Richard ^d   Krieger, Otto ^e   Baldinger, Christian ^b   Klocker, Joerg ^b   Pont, Joerg ^f   Oberaigner, Willhelm ^g  

^a KEPLER UNIVERSITY HOSPITAL   (Austria)

^b LKH Salzburg ^*  (Austria)

^c UNIVERSITY OF GRAZ   (Austria)

^d UNIVERSITY OF INNSBRUCK   (Austria)

^e KH Elisabethinen   (Austria)

^f KFJ Hospital   (Austria)

^g Inst for Clinical Tumor Epidemiol   (Austria)

Author keywords

Antineoplastic combined chemotherapy protocols; Drug therapy; Large cell lymphoma; Lymphoma

Indexed keywords

ANTINEOPLASTIC AGENT; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOXORUBICIN; EPIRUBICIN; ETOPOSIDE; FOLINATE CALCIUM; HYDROXYUREA; IFOSFAMIDE; IMATINIB; IODINE; MESNA; METHOTREXATE; PREDNISOLONE; PREDNISONE; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; VINCRISTINE;

ADULT; AGE; AGED; ARTICLE; B CELL LYMPHOMA; BILE DUCT CARCINOMA; BURKITT LYMPHOMA; CANCER PATIENT; CANCER SURVIVAL; CHRONIC MYELOID LEUKEMIA; CLINICAL OBSERVATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEATH; DOSE RESPONSE; FOLLOW UP; HIGH RISK PATIENT; HUMAN; KIDNEY CARCINOMA; LARGE CELL LYMPHOMA; LYMPHOBLASTOMA; LYMPHOMA; MAJOR CLINICAL STUDY; MELANOMA; MULTICENTER STUDY; NEPHRECTOMY; PRIORITY JOURNAL; PROGNOSIS; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; RELAPSE; SIDE EFFECT; T CELL LYMPHOMA; THYROID PAPILLARY CARCINOMA; THYROIDECTOMY; TREATMENT OUTCOME;

AGE FACTORS; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAUSE OF DEATH; CYCLOPHOSPHAMIDE; DEXAMETHASONE; EPIRUBICIN; ETOPOSIDE; HUMANS; IFOSFAMIDE; LONGITUDINAL STUDIES; LYMPHOMA; MESNA; METHOTREXATE; MIDDLE AGED; PREDNISONE; SURVIVAL ANALYSIS; TREATMENT FAILURE; TREATMENT OUTCOME; VINCRISTINE;

EID: 15844418260     PISSN: 09395555     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00277-004-0936-x     Document Type: Article

References (21)

1. André M, Mounier N, Leleu X, et al. (2004) Second cancers and late toxicities after treatment of aggressive non-Hodgkin lymphoma with the ACVBP regimen: A FELA cohort study on 2837 patients. Blood 103:1222-1228
2. Armitage JO, Dick FR, Corder MP, et al. (1982) Predicting outcome in patients with diffuse histiocytic lymphoma treated with cyclophosphamide, adriamycin, vincristine and prednisone (CHOP). Cancer 50:1695-1702 1:STN:280:BiyD3c7mt1w%3D
3. Blayney DW, LeBlanc ML, Grogan T, et al. (2003) Dose intense, every 2 weeks with dose-intense cyclophosphamide, doxorubicin, vincristine, and prednisone may improve survival in intermediate- and high-grade lymphoma: A phase II study of the Southwest Oncology Group (SWOG 9349). J Clin Oncol 21:2466-2473 10.1200/JCO.2003.06.137
4. Bostrom BC, Sensel MR, Sather HN, et al. (2003) Dexamethasone versus prednisone and daily oral versus weekly intravenous mercaptopurine for patients with standard-risk acute lymphoblastic leukemia: A report from the Children's Cancer Group. Blood 101:3809-3817 10.1182/ blood-2002-08-2454
5. Coiffier B (1995) Fourteen years of high dose CHOP (ACVB-regimen): Preliminary conclusions about the treatment of aggressive lymphoma patients. Ann Oncol 6:211-217 1:STN:280:ByqA3snpsFM%3D
6. Coiffier B (2003) Increasing chemotherapy intensity in aggressive lymphomas: A renewal? J Clin Oncol 21:2457-2459 10.1200/JCO.2003.93.116
7. Coiffier B, Lepage E, Briere J, et al. (2002) CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 346:235-242 10.1056/NEJMoa011795
8. Coltman CA, Luce JK, McKelvey EM, et al. (1977) Chemotherapy of non-Hodgkin's lymphoma: Ten years experience in the Southwest Oncology Group. Cancer Treat Rep 61:1067-1078 71206
9. Dixon DO, McLaughlin P, Hagemeister FB, et al. (1987) Reporting outcomes in Hodgkin's disease and lymphoma. J Clin Oncol 5:1670-1672 1:STN:280:BieD3M%2Fht10%3D
10. Dumontet C, Bastion Y, Felman P, et al. (1992) Long-term outcome and sequelae in aggressive lymphoma patients treated with the LNH-80 regimen. Ann Oncol 3:639-644 1:STN:280:ByyD1c7jt10%3D
11. Ferreri AJM, Abrey LE, Blay JY, et al. (2003) Summary statement on primary central nervous system lymphomas from the Eighth International Conference on Malignant Lymphoma, Lugano, Switzerland, June 12 to 15, 2002. J Clin Oncol 21:2407-2414 10.1200/JCO.2003.01.135
12. Fisher RI, Gaynor ER, Dahlberg S, et al. (1993) Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma. N Engl J Med 328:1002-1006 10.1056/ NEJM199304083281404
13. Fridrik MA, Hausmaninger H, Linkesch W, et al. (1996) CEOP-IMVP-Dexa in the treatment of aggressive lymphomas: An Austrian multicenter trial. J Clin Oncol 14:227-232
14. Fridrik MA, Greil R, Hausmaninger H, et al. (1997) Randomized open label phase III trial of CEOP/IMVP-Dexa alternating chemotherapy and filgrastim versus CEOP/IMVP-Dexa alternating chemotherapy for aggressive non-Hodgkin's lymphoma (NHL). A multicenter trial by the Austrian Working Group for Medical Tumor Therapy. Ann Hematol 75:135-140 10.1007/ s002770050330
15. Gisselbrecht C, Lepage E, Molina T, et al. (2002) Shortened first-line high-dose chemotherapy for patients with poor-prognosis aggressive lymphoma. J Clin Oncol 20:2472-2479 10.1200/JCO.2002.02.125
16. Lee AY, Connors JM, Klimo P, et al. (1997) Late relapse in patients with diffuse large-cell lymphoma treated with MACOP-B. J Clin Oncol 15:1745-1753 1:CAS:528:DyaK2sXjsVCmu7k%3D
17. Leung W, Sandlund JT, Hudson MM, et al. (2001) Second malignancy after treatment of childhood non-Hodgkin lymphoma. Cancer 92:1959-1966 10.1002/ 1097-0142(20011001)92:7<1959::AID-CNCR1715>3.0.CO;2-Y
18. Pfreundschuh M, Truemper L, Kloess M, et al. (2004) 2-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of young patients with good prognosis (normal LDH) aggressive lymphomas: Results of the NHL-B1 trial of the DSHNHL Blood First Edition Paper, prepublished online 24 February 2004. Blood 104:626-633
19. Shipp MA (1993) The International Non-Hodgkin's Lymphoma Prognostic Factors Project. A predictive model for aggressive non-Hodgkin's lymphoma. N Engl J Med 329:987-994 10.1056/NEJM199309303291402
20. The Non-Hodgkin's Lymphoma Classification Project (1997) A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin's lymphoma. Blood 89:3909-3918
21. Verdonk LF, Vanputten W, Hagenbeek A, et al. (1995) Comparison of CHOP chemotherapy with autologous bone marrow transplantation for slowly responding patients with aggressive non-Hodgkin's lymphoma. N Engl J Med 332:1045-1051 10.1056/NEJM199504203321601